1.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

2.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

3.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

4.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

5.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

6.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

7.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

8.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

9.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

1.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

2.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

3.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

4.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

5.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

6.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

7.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

8.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

9.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

1.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

2.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

3.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

4.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

5.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

6.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

7.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

8.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

9.

The spatial diffusion of nonmarital cohabitation in Belgium over 25 years: Geographic proximity and urban hierarchy

1.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

2.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

3.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

4.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

5.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

6.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

7.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

8.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

9.

Feasibility and cost of FH cascade screening in Belgium (BEL-CASCADE) including a novel rapid rule-out strategy.

1.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

2.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

3.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

4.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

5.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

6.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

7.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

8.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

9.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

1.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

2.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

3.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

4.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

5.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

6.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

7.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

8.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

9.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

1.

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020.

2.

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020.

3.

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020.

4.

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020.

5.

Exploiting genomic surveillance to map the spatio-temporal dispersal of SARS-CoV-2 spike mutations in Belgium across 2020.

1.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of...

2.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of...

1.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

2.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

3.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

4.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

5.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

6.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

7.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

8.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

9.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

1.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

2.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

3.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

4.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

5.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

6.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

7.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

8.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

9.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.